946 related articles for article (PubMed ID: 16153456)
21. RANK-Fc: a therapeutic antagonist for RANK-L in myeloma.
Sordillo EM; Pearse RN
Cancer; 2003 Feb; 97(3 Suppl):802-12. PubMed ID: 12548579
[TBL] [Abstract][Full Text] [Related]
22. TNF receptor type 1 regulates RANK ligand expression by stromal cells and modulates osteoclastogenesis.
Abu-Amer Y; Abbas S; Hirayama T
J Cell Biochem; 2004 Nov; 93(5):980-9. PubMed ID: 15389885
[TBL] [Abstract][Full Text] [Related]
23. Human cord blood monocytes undergo terminal osteoclast differentiation in vitro in the presence of culture medium conditioned by giant cell tumor of bone.
Roux S; Quinn J; Pichaud F; Orcel P; Chastre E; Jullienne A; De Vernejoul MC
J Cell Physiol; 1996 Sep; 168(3):489-98. PubMed ID: 8816903
[TBL] [Abstract][Full Text] [Related]
24. Two distinct cellular mechanisms of osteoclast formation and bone resorption in periprosthetic osteolysis.
Sabokbar A; Kudo O; Athanasou NA
J Orthop Res; 2003 Jan; 21(1):73-80. PubMed ID: 12507582
[TBL] [Abstract][Full Text] [Related]
25. Malignant B-lymphoid cells with bone lesions express receptor activator of nuclear factor-kappaB ligand and vascular endothelial growth factor to enhance osteoclastogenesis.
Shibata H; Abe M; Hiura K; Wilde J; Moriyama K; Sano T; Kitazoe K; Hashimoto T; Ozaki S; Wakatsuki S; Kido S; Inoue D; Matsumoto T
Clin Cancer Res; 2005 Sep; 11(17):6109-15. PubMed ID: 16144909
[TBL] [Abstract][Full Text] [Related]
26. Interface tissue fibroblasts from loose total hip replacement prosthesis produce receptor activator of nuclear factor-kappaB ligand, osteoprotegerin, and cathepsin K.
Mandelin J; Li TF; Hukkanen M; Liljeström M; Salo J; Santavirta S; Konttinen YT
J Rheumatol; 2005 Apr; 32(4):713-20. PubMed ID: 15801030
[TBL] [Abstract][Full Text] [Related]
27. Regulation of osteoclastogenesis by gap junction communication.
Matemba SF; Lie A; Ransjö M
J Cell Biochem; 2006 Oct; 99(2):528-37. PubMed ID: 16639710
[TBL] [Abstract][Full Text] [Related]
28. Inflammatory T cells rapidly induce differentiation of human bone marrow stromal cells into mature osteoblasts.
Rifas L; Arackal S; Weitzmann MN
J Cell Biochem; 2003 Mar; 88(4):650-9. PubMed ID: 12577299
[TBL] [Abstract][Full Text] [Related]
29. Osteoprotegerin overexpression by breast cancer cells enhances orthotopic and osseous tumor growth and contrasts with that delivered therapeutically.
Fisher JL; Thomas-Mudge RJ; Elliott J; Hards DK; Sims NA; Slavin J; Martin TJ; Gillespie MT
Cancer Res; 2006 Apr; 66(7):3620-8. PubMed ID: 16585187
[TBL] [Abstract][Full Text] [Related]
30. Gene expression of osteoprotegerin ligand, osteoprotegerin, and receptor activator of NF-kappaB in giant cell tumor of bone: possible involvement in tumor cell-induced osteoclast-like cell formation.
Huang L; Xu J; Wood DJ; Zheng MH
Am J Pathol; 2000 Mar; 156(3):761-7. PubMed ID: 10702390
[TBL] [Abstract][Full Text] [Related]
31. Inhibitory effect of CGRP on osteoclast formation by mouse bone marrow cells treated with isoproterenol.
Ishizuka K; Hirukawa K; Nakamura H; Togari A
Neurosci Lett; 2005 Apr; 379(1):47-51. PubMed ID: 15814197
[TBL] [Abstract][Full Text] [Related]
32. Osteoprotegerin inhibits tumor-induced osteoclastogenesis and bone tumor growth in osteopetrotic mice.
Clohisy DR; Ramnaraine ML; Scully S; Qi M; Van G; Tan HL; Lacey DL
J Orthop Res; 2000 Nov; 18(6):967-76. PubMed ID: 11192258
[TBL] [Abstract][Full Text] [Related]
33. Synovial tissue in rheumatoid arthritis is a source of osteoclast differentiation factor.
Gravallese EM; Manning C; Tsay A; Naito A; Pan C; Amento E; Goldring SR
Arthritis Rheum; 2000 Feb; 43(2):250-8. PubMed ID: 10693863
[TBL] [Abstract][Full Text] [Related]
34. Expression of osteoprotegerin (OPG), TNF related apoptosis inducing ligand (TRAIL), and receptor activator of nuclear factor kappaB ligand (RANKL) in human breast tumours.
Van Poznak C; Cross SS; Saggese M; Hudis C; Panageas KS; Norton L; Coleman RE; Holen I
J Clin Pathol; 2006 Jan; 59(1):56-63. PubMed ID: 16394281
[TBL] [Abstract][Full Text] [Related]
35. RANKL protein is expressed at the pannus-bone interface at sites of articular bone erosion in rheumatoid arthritis.
Pettit AR; Walsh NC; Manning C; Goldring SR; Gravallese EM
Rheumatology (Oxford); 2006 Sep; 45(9):1068-76. PubMed ID: 16490750
[TBL] [Abstract][Full Text] [Related]
36. PTHrP increases RANKL expression by stromal cells from giant cell tumor of bone.
Cowan RW; Singh G; Ghert M
J Orthop Res; 2012 Jun; 30(6):877-84. PubMed ID: 22102368
[TBL] [Abstract][Full Text] [Related]
37. Expression and localization of extracellular matrix metalloproteinase inducer in giant cell tumor of bone.
Si AI; Huang L; Xu J; Kumta SM; Wood D; Zheng MH
J Cell Biochem; 2003 Aug; 89(6):1154-63. PubMed ID: 12898514
[TBL] [Abstract][Full Text] [Related]
38. Osteoprotegerin inhibits osteoclast formation and bone resorbing activity in giant cell tumors of bone.
Atkins GJ; Bouralexis S; Haynes DR; Graves SE; Geary SM; Evdokiou A; Zannettino AC; Hay S; Findlay DM
Bone; 2001 Apr; 28(4):370-7. PubMed ID: 11336917
[TBL] [Abstract][Full Text] [Related]
39. The molecular triad OPG/RANK/RANKL: involvement in the orchestration of pathophysiological bone remodeling.
Theoleyre S; Wittrant Y; Tat SK; Fortun Y; Redini F; Heymann D
Cytokine Growth Factor Rev; 2004 Dec; 15(6):457-75. PubMed ID: 15561602
[TBL] [Abstract][Full Text] [Related]
40. Characterization of osteoprotegerin binding to glycosaminoglycans by surface plasmon resonance: role in the interactions with receptor activator of nuclear factor kappaB ligand (RANKL) and RANK.
Théoleyre S; Kwan Tat S; Vusio P; Blanchard F; Gallagher J; Ricard-Blum S; Fortun Y; Padrines M; Rédini F; Heymann D
Biochem Biophys Res Commun; 2006 Aug; 347(2):460-7. PubMed ID: 16828054
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
